OVARIAN CANCER

A new study shows that moderate physical exercise may help women reduce the risk of ovarian cancer. The study was supported by a healthy lifestyle can prevent women tumor development of this theory.

Public Health Agency of Canada study on 442 women with ovarian cancer and did not have ovarian cancer, the situation is similar 2,135 women conducted a questionnaire of the survey. According to the survey findings, which sports the highest levels of women, the risk of suffering from ovarian cancer has been noticeably reduced. Regular exercise the highest level of women suffering from ovarian cancer risk reduction of 33%; The level of the highest female, the <BR> risk reduction of 27%.

Researchers in the United States recently claimed that women Wan children may reduce the risk of ovarian cancer.

The University of Southern California study of 477 patients with ovarian cancer and 660 the same race, same age and same area of women's health survey found that the children of women in Wan Ovarian cancer risk lower.

Georgetown University Medical Center and the North Carolina State University researchers using tobacco to produce antibodies for the human papilloma (HPV) virus gene fragments. This project has been $ 3 million of government funding. Georgetown University study for Dr. Kencomh Dretchen said, because HPV is the main risk factors of cervical cancer, the objective of this study is to be against the virus antibodies.

He said, "I do not know what reasons, in normal circumstances HPV difficult to growth and development." Therefore, we extracted from the HPV genetic material transplanted to the tobacco virus to amplified fragment.

Despite preventive ovariectomy in the prevention of high-risk patients with ovarian cancer in a certain role, but still cautious, because ovarian cancer and distinguish the cavity cancer can occur. In one study, 16 of 28 high-risk family members to preventive ovariectomized later, three occurred, and diffuse abdominal cancer. These high-risk patients, and that the author: genetic susceptibility not only confined to the ovary, but also extends to occur in embryos with ovarian related organizations. Formerly, reported preventive nest after resection of 324 cases of women, six cases (1.8%) of the peritoneum of the original tumor. Therefore, the preventive after resection of primary ovarian peritoneal tumor, and less common, the incidence rate of about 2%.

【Medical industry network HealthDayNews2003 According to the July 3 - now on the younger female epithelial ovarian cancer, some important information: your chances of survival much more than older patients.

In July, "Obstetrics and Gynecology" (Obstetrics andGynecology), the journal published a new study, the researchers found: diagnosis of advanced epithelial ovarian cancer in women aged under 45 of the 5-year survival than those over the age of 45 is two times bigger. "If all other aspects of the same, young patients can live better," the author, Stamford University professor Chen (JohnChan): In fact, even if it is possible to study the impact of factors, such as other health problems, age patients still live better.

Denmark Gronloud such report, as paclitaxel plus platinum chemotherapy after complete remission in patients with ovarian cancer, if recurrence of a solitary lesion again cytoreductive surgery may improve survival. (Eur J Surg Oncol 2005,31:67)

In the retrospective study selected criteria: 1 Guide to the residual initial stage operation and confirmed by histological examination of epithelial ovarian cancer; (2) complete remission after first-line treatment; 3. Imaging confirmed pots peritoneal metastasis; (4) Surgical resection of lesions for the purpose.

Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates generally below 30%, mainly in patients with relapsing most (about 75%), relapse after chemotherapy to poor results.

For the treatment of recurrent ovarian cancer chemotherapy drugs many, no less than 10 species, but only clinical remission rate of 20% to 30%, no progress median survival time (PFS) for 2 to 6 months, the median overall survival (OS) for six to 12 months. Therefore, to improve the efficacy of chemotherapy drugs delay, but the development of new drugs is very difficult, efficient use of existing drugs is an effective way to <BR>.

Researchers reported that the joint use of both cisplatin and paclitaxel chemotherapy drug for ovarian cancer achieved better clinical remission rate and a higher survival rate, this new program has become advanced ovarian cancer patients with standard treatment programs.

From the European Organization for Cancer Research and Treatment of Dr Piccart, a group of researchers across the Atlantic to the two large-scale clinical trials group that cisplatin and paclitaxel (TP) both chemotherapy treatment of advanced ovarian cancer with significant advantages.

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

The United States - a study found, abdominal pain and distension, and ovarian cancer-related symptoms, usually in the months before diagnosis will appear. This shows that the use of appropriate methods of early diagnosis of ovarian cancer, timely treatment to reduce deaths.
According to a Reuters report, the University of California research study found that patients with breast cancer and non-cancer than women with ovarian cancer are more vulnerable to representation symptoms, the most notable of these patients are diagnosed in the first half of the abdominal pain and distension. Researchers in the October edition of the American "cancer" on the magazine report said that the current practice is to use general diagnostic imaging abdominal and pelvic imaging and CA125 to confirm the diagnosis of ovarian cancer. The researchers suggested that doctors should consider allowing representation of the above symptoms of ovarian cancer early women do pelvic imaging and CA125 to early treatment.